{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:53:11Z","timestamp":1790787191436,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01536-6","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:33:02Z","timestamp":1759894382000},"page":"3495-3511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6993","authenticated-orcid":false,"given":"Maria","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Berardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Maria","family":"Magnanimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"12","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"key":"1536_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","volume":"368","author":"MI Asher","year":"2006","unstructured":"Asher MI, Montefort S, Bjo\u0308rkst\u00e9n B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhino conjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicounty cross-sectional surveys. Lancet. 2006;368:733\u201343.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8\u201316.","journal-title":"Ann Nutr Metab"},{"issue":"5","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155\u201362.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1536_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","volume":"134","author":"N Dhingra","year":"2014","unstructured":"Dhingra N, Shemer A, da Rosa JC, Rozenblit M, Fuentes-Duculan J, Gittler JK, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362\u201372.","journal-title":"J Allergy Clin Immunol"},{"key":"1536_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","volume":"136","author":"M Su\u00e1rez-Fari\u00f1as","year":"2015","unstructured":"Su\u00e1rez-Fari\u00f1as M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, et al. Alopecia areata profiling shows TH1, TH2, and IL \u221223 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol. 2015;136:1277\u201387.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/cea.13729","volume":"50","author":"YH Wei","year":"2020","unstructured":"Wei YH, Tai YH, Dai YX, Chang YT, Chen TJ, Chen MH. Bidirectional association between alopecia areata and atopic dermatitis: a population-based cohort study in Taiwan. Clin Exp Allergy. 2020;50(12):1406\u201314.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1536_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/12034754211027858","volume":"26","author":"L Belmesk","year":"2022","unstructured":"Belmesk L, Muntyanu A, Cantin E, et al. Prominent role of type 2 immunity in skin diseases: beyond atopic dermatitis. J Cutan Med Surg. 2022;26(1):33\u201349.","journal-title":"J Cutan Med Surg"},{"key":"1536_CR9","doi-asserted-by":"publisher","first-page":"1279976","DOI":"10.3389\/fimmu.2024.1279976","volume":"15","author":"Q Chen","year":"2024","unstructured":"Chen Q, Yang X, Ni B, Song Z. Atopy in chronic urticaria: an important yet overlooked issue. Front Immunol. 2024;15:1279976.","journal-title":"Front Immunol"},{"issue":"5","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamadermatol.2018.0141","volume":"154","author":"R Thomi","year":"2018","unstructured":"Thomi R, Cazzaniga S, SeyedJafari SM, Schlapbach C, Hunger RE. Association of Hidradenitis Suppurativa with T Helper 1\/T Helper 17 phenotypes: a semantic map analysis. JAMA Dermatol. 2018;154(5):592\u20135.","journal-title":"JAMA Dermatol"},{"key":"1536_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2017","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68\u201373.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1536_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2774","volume":"98","author":"C Zeidler","year":"2018","unstructured":"Zeidler C, Tsianakas A, Pereira M, St\u00e4nder H, Yosipovitch G, St\u00e4nder S. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.3390\/ijms23105518","volume":"23","author":"YC Tsai","year":"2022","unstructured":"Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. Int J Mol Sci. 2022;23(10):5518.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1536_CR14","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/JAA.S492614","volume":"3","author":"X Shao","year":"2024","unstructured":"Shao X, Pan X, Chen Y, Zhu Y, Chen S, Chen J. Concurrent refractory atopic dermatitis and generalized vitiligo successfully treated with abrocitinib: a case report. J Asthma Allergy. 2024;3(17):1259\u201363.","journal-title":"J Asthma Allergy"},{"issue":"3","key":"1536_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40257-017-0340-7","volume":"19","author":"JL Owen","year":"2018","unstructured":"Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018;19(3):293\u2013302.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1536_CR16","first-page":"139","volume":"110","author":"H Johnson","year":"2022","unstructured":"Johnson H, Novack DE, Adler BL, Yu J. Can atopic dermatitis and allergic contact dermatitis coexist? Cutis. 2022;110(3):139\u201342.","journal-title":"Cutis"},{"issue":"3","key":"1536_CR17","first-page":"249","volume":"82","author":"RP Usatine","year":"2010","unstructured":"Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82(3):249\u201355.","journal-title":"Am Fam Physician"},{"issue":"3","key":"1536_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12016-021-08875-0","volume":"61","author":"Y Li","year":"2021","unstructured":"Li Y, Li L. Contact dermatitis: classifications and management. Clin Rev Allergy Immunol. 2021;61(3):245\u201381.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1536_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jaad.2019.03.020","volume":"81","author":"M Stout","year":"2019","unstructured":"Stout M, Silverberg JI. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. J Am Acad Dermatol. 2019;81(1):157\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1536_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2023.10.029","volume":"90","author":"S Bocquel","year":"2024","unstructured":"Bocquel S, Soria A, Raison-Peyron N, et al. Impact of dupilumab on patch test results and allergic contact dermatitis: a prospective multicenter study. J Am Acad Dermatol. 2024;90(3):512\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1536_CR21","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1111\/jdv.18099","volume":"36","author":"YG Koh","year":"2022","unstructured":"Koh YG, Park JW, Shin SH, Kim BJ, Yoo KH. Dupilumab for the treatment of refractory allergic contact dermatitis from rubber\/latex concomitant with atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(8):e640\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1536_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.115.223784","volume":"354","author":"T Fukuyama","year":"2015","unstructured":"Fukuyama T, Ehling S, Cook E, B\u00e4umer W. Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394\u2013405.","journal-title":"J Pharmacol Exp Ther"},{"key":"1536_CR23","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0539","author":"L Potestio","year":"2025","unstructured":"Potestio L, Patruno C, Feo F, Coronella L, di Vico F, Napolitano M. Effectiveness of Janus kinase inhibitors for the management of atopic dermatitis and concomitant occupational allergic contact dermatitis: a real-life study. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2024.0539.","journal-title":"Dermatitis"},{"issue":"1","key":"1536_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/cod.13134","volume":"80","author":"C Collantes-Rodr\u00edguez","year":"2019","unstructured":"Collantes-Rodr\u00edguez C, Jim\u00e9nez-Gallo D, Ossorio-Garc\u00eda L, Villegas-Romero I, Linares-Barrios M. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab. Contact Dermat. 2019;80(1):69\u201370.","journal-title":"Contact Dermat"},{"issue":"11","key":"1536_CR25","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.3390\/ijms25115652","volume":"25","author":"I \u0160uti\u0107Udovi\u0107","year":"2024","unstructured":"\u0160uti\u0107Udovi\u0107 I, Hla\u010da N, Massari LP, Brajac I, Ka\u0161telan M, Vi\u010di\u0107 M. Deciphering the complex immunopathogenesis of alopecia areata. Int J Mol Sci. 2024;25(11):5652.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1536_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ced\/llac104","volume":"48","author":"S Holmes","year":"2023","unstructured":"Holmes S, Harries M, Macbeth AE, Chiu WS, de Lusignan S, Messenger AG, et al. Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study. Clin Exp Dermatol. 2023;48(4):325\u201331.","journal-title":"Clin Exp Dermatol"},{"key":"1536_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17643","author":"Y Ma","year":"2025","unstructured":"Ma Y, Chachin M, Hirose T, Nakamura K, Shi N, Hiro S, et al. Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database. J Dermatol. 2025. https:\/\/doi.org\/10.1111\/1346-8138.17643.","journal-title":"J Dermatol"},{"issue":"9","key":"1536_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","volume":"20","author":"C Goh","year":"2006","unstructured":"Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20(9):1055\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1536_CR29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s13555-025-01425-y","volume":"15","author":"J Seneschal","year":"2025","unstructured":"Seneschal J, FiguerasNart L, Sabatino S, Papadimitropoulos M, Dabral S, Lampropoulou A. Real-world evidence for baricitinib in the treatment of atopic dermatitis and Alopecia areata: systematic literature review 2020\u20132023. Dermatol Ther (Heidelb). 2025;15(7):1719\u201354.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1536_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40257-023-00805-4","volume":"24","author":"S Ly","year":"2023","unstructured":"Ly S, Manjaly P, Kamal K, Shields A, Wafae B, Afzal N, et al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am J Clin Dermatol. 2023;24(6):875\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1536_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2500\/aap.2018.39.4166","volume":"39","author":"NA Kitsioulis","year":"2018","unstructured":"Kitsioulis NA, Papadopoulos NG, Kostoudi S, Manousakis E, Douladiris N, Xepapadaki P. Assessment of atopic dermatitis as a risk factor for chronic spontaneous urticaria in a pediatric population. Allergy Asthma Proc. 2018;39(6):445\u20138.","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"1536_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/pai.13457","volume":"32","author":"I Lachover-Roth","year":"2021","unstructured":"Lachover-Roth I, Rabie A, Cohen-Engler A, Rosman Y, Meir-Shafrir K, Confino-Cohen R. Chronic urticaria in children: new insights from a large cohort. Pediatr Allergy Immunol. 2021;32(5):999\u20131005.","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"1536_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3904\/kjim.2014.29.6.800","volume":"29","author":"GY Ban","year":"2014","unstructured":"Ban GY, Kim MY, Yoo HS, et al. Clinical features of elderly chronic urticaria. Korean J Intern Med. 2014;29(6):800\u20136.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"1536_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100097","volume":"13","author":"MN Ghazanfar","year":"2020","unstructured":"Ghazanfar MN, Kibsgaard L, Thomsen SF, Vestergaard C. Risk of comorbidities in patients diagnosed with chronic urticaria: a nationwide registry-study. World Allergy Organ J. 2020;13(1):100097.","journal-title":"World Allergy Organ J"},{"issue":"10","key":"1536_CR35","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590\u20138.","journal-title":"Am Fam Physician"},{"issue":"10450","key":"1536_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gim\u00e9nez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024;404(10450):393\u2013404.","journal-title":"Lancet"},{"issue":"1","key":"1536_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394.","journal-title":"J Allergy Clin Immunol"},{"key":"1536_CR38","first-page":"990","volume":"8","author":"PM Heil","year":"2010","unstructured":"Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course: a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1536_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2005.12.045","volume":"55","author":"PG Vigo","year":"2006","unstructured":"Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55:168\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1536_CR40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2500\/aap.2008.29.3160","volume":"29","author":"LE Sheinkopf","year":"2008","unstructured":"Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530\u20137.","journal-title":"Allergy Asthma Proc"},{"issue":"10","key":"1536_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102807","volume":"11","author":"E Robak","year":"2022","unstructured":"Robak E, Robak T. Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J Clin Med. 2022;11(10):2807.","journal-title":"J Clin Med"},{"issue":"2","key":"1536_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB. Clinical practice: Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"1536_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa foundations: part II\u2014topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1536_CR44","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaad.2020.12.051","volume":"85","author":"S Sherman","year":"2021","unstructured":"Sherman S, Kridin K, Bitan DT, Leshem YA, Hodak E, Cohen AD. Hidradenitis suppurativa and atopic dermatitis: a 2-way association. J Am Acad Dermatol. 2021;85(6):1473\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1536_CR45","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1111\/jdv.16280","volume":"34","author":"A Gambardella","year":"2020","unstructured":"Gambardella A, Calabrese G, Di Brizzi EV, Alfano R, Argenziano G. A case of atopic dermatitis and hidradenitis suppurativa successfully treated with Dupilumab. J Eur Acad Dermatol Venereol. 2020;34(6):e284\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1536_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15645","volume":"35","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Sapigni C, Simonetti O, Radi G, Gambini D, Maurizi A, et al. Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa. Dermatol Ther. 2022;35(8):e15645.","journal-title":"Dermatol Ther"},{"issue":"12","key":"1536_CR47","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1111\/ced.15387","volume":"47","author":"MK Cho","year":"2022","unstructured":"Cho MK, Shin JU, Kim DH, Lee HJ. Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab. Clin Exp Dermatol. 2022;47(12):2303\u20135.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1536_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.annder.2023.03.006","volume":"150","author":"N Kluger","year":"2023","unstructured":"Kluger N. Failure of dupilumab in a severe case of hidradenitis suppurativa. Ann Dermatol Venereol. 2023;150(3):241\u20132.","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"1536_CR49","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","volume":"92","author":"LS Ackerman","year":"2025","unstructured":"Ackerman LS, Schlosser BJ, Zhan T, Prajapati VH, Fretzin S, Takahashi H, et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2025;92(6):1252\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1536_CR50","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","volume":"29","author":"L Ackerman","year":"2023","unstructured":"Ackerman L, Acloque G, Bacchelli S, Schwartz H, Feinstein BJ, La Stella P, et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med. 2023;29(12):3127\u201336.","journal-title":"Nat Med"},{"issue":"3","key":"1536_CR51","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1536_CR52","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","volume":"83","author":"KA Williams","year":"2020","unstructured":"Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1536_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ijd.17493","volume":"64","author":"W Li","year":"2025","unstructured":"Li W, Pi Y, Xu J. Association between atopic dermatitis and prurigo nodularis: a systematic review and meta-analysis. Int J Dermatol. 2025;64(2):282\u20136.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1536_CR54","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390.","journal-title":"Nat Med"},{"issue":"6","key":"1536_CR55","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","volume":"190","author":"V Liao","year":"2024","unstructured":"Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024;190(6):798\u2013810.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1536_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/DER.0000000000000517","volume":"31","author":"M Napolitano","year":"2020","unstructured":"Napolitano M, Fabbrocini G, Scalvenzi M, Nistic\u00f2 SP, Dastoli S, Patruno C. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020;31(1):81\u20134.","journal-title":"Dermatitis"},{"issue":"4","key":"1536_CR57","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/09546634.2019.1659479","volume":"32","author":"S Ferrucci","year":"2021","unstructured":"Ferrucci S, Tavecchio S, Berti E, Angileri L. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2021;32(4):453\u20134.","journal-title":"J Dermatolog Treat"},{"key":"1536_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdin.2023.06.005","volume":"13","author":"YW Yew","year":"2023","unstructured":"Yew YW, Yeo PM. Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore. JAAD Int. 2023;13:13\u20134.","journal-title":"JAAD Int."},{"issue":"1","key":"1536_CR59","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.abd.2022.01.011","volume":"98","author":"S Mitsuyama","year":"2023","unstructured":"Mitsuyama S, Higuchi T. Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis. An Bras Dermatol. 2023;98(1):86\u20139.","journal-title":"An Bras Dermatol"},{"issue":"2","key":"1536_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaad.2023.04.056","volume":"89","author":"E Pezzolo","year":"2023","unstructured":"Pezzolo E, Gambardella A, Guanti M, et al. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study. J Am Acad Dermatol. 2023;89(2):430\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1536_CR61","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.asjsur.2024.02.127","volume":"47","author":"F Lou","year":"2024","unstructured":"Lou F, Wang Y, Xiao Y, Liu Y. Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis. Asian J Surg. 2024;47(7):3084\u20138.","journal-title":"Asian J Surg"},{"issue":"5","key":"1536_CR62","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jaad.2024.06.094","volume":"91","author":"E Pezzolo","year":"2024","unstructured":"Pezzolo E, Narcisi A, Gargiulo L, et al. Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study. J Am Acad Dermatol. 2024;91(5):e147\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1536_CR63","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E. Psoriasis: epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314\u201320.","journal-title":"Clin Exp Dermatol"},{"issue":"9997","key":"1536_CR64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"key":"1536_CR65","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","volume":"162","author":"M Augustin","year":"2010","unstructured":"Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Scha\u0308fer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1536_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.29","volume":"1","author":"A Cunliffe","year":"2021","unstructured":"Cunliffe A, Gran S, Ali U, Grindlay D, Lax SJ, Williams HC, et al. Can atopic eczema and psoriasis coexist? A systematic review and meta-analysis. Skin Health Dis. 2021;1(2):e29.","journal-title":"Skin Health Dis"},{"issue":"3","key":"1536_CR67","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","volume":"86","author":"CM Brumfiel","year":"2022","unstructured":"Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2022;86(3):708\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1536_CR68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/all.15921","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Welchowski T, Schmid M, Maintz L, Herrmann N, Wilsmann-Theis D, et al. Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the \u2018Flip-Flop\u2019 phenomenon). Allergy. 2024;79(1):164\u201373.","journal-title":"Allergy"},{"issue":"10","key":"1536_CR69","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ijd.14055","volume":"57","author":"AM Dahir","year":"2018","unstructured":"Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157\u201364.","journal-title":"Int J Dermatol"},{"issue":"8","key":"1536_CR70","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jocd.13263","volume":"19","author":"P Acharya","year":"2020","unstructured":"Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(8):2016\u201320.","journal-title":"J Cosmet Dermatol"},{"key":"1536_CR71","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151:522\u20138.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1536_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200873","volume":"34","author":"T Pan","year":"2023","unstructured":"Pan T, Mu Y, Shi X, Chen L. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report. J Dermatolog Treat. 2023;34(1):2200873.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1536_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000544703","volume":"17","author":"LM Magnanimi","year":"2025","unstructured":"Magnanimi LM, De Berardinis A, Esposito M, Fargnoli MC. Upadacitinib monotherapy in vitiligo associated with atopic dermatitis: killing two birds with one stone. Case Rep Dermatol. 2025;17(1):91\u20135.","journal-title":"Case Rep Dermatol"},{"key":"1536_CR74","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","volume":"89","author":"X Su","year":"2023","unstructured":"Su X, Luo R, Ruan S, Zhong Q, Zhuang Z, Xiao Z, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo. J Am Acad Dermatol. 2023;89:1257\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"1536_CR75","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01536-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01536-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01536-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:02:57Z","timestamp":1763200977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01536-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01536-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maria Esposito has served as speaker\/consultant for Abbvie, Amgen, Almirall, Boehringer Ingelheim, Eli Lilly, Janssen, Leopharma, Novartis, Pfizer, Sanofi Regeneron and UCB. Alessandro Giunta has served as speaker\/consultant for Abbvie, Boehringer-Ingelheim, Eli Lilly, Novartis, Sandoz and UCB. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and\/or research grants from AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi-Regeneron and Sunpharma. Cataldo Patruno has acted as speaker, consultant and\/or advisory board member AbbVie, Almirall, Amgen, Galderma, Leo Pharma, Lilly, Novartis, Pfizer, Pierre Fabre and Sanofi. Maddalena Napolitano has acted as speaker, consultant and\/or advisory board member for Abbvie, Eli Lilly, Leo Pharma, Novartis, Incyte and Sanofi. Andrea De Berardinis, Luca Potestio and Lina Maria Magnanimi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}